Litigation Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Docket	1:12-cv-00247	Date Filed	2012-02-29
Court	District Court, D. Delaware	Date Terminated	2013-07-23
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	Plaintiff	Referred To
Patents	6,200,604; 7,862,832; 7,862,833
Link to Docket	External link to docket

Details for Cephalon Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-02-29				External link to document

Cephalon Inc. v. Mylan Pharmaceuticals Inc., 1:12-cv-00247: Litigation Summary and Patent Analysis

Last updated: August 6, 2026

Cephalon Inc. v. Mylan Pharmaceuticals Inc., No. 1:12-cv-00247, was a Hatch-Waxman patent dispute involving Mylan’s abbreviated new drug application for generic armodafinil, marketed by Cephalon as Nuvigil. The principal patent at issue was U.S. Patent No. 7,132,570, which covered the single-enantiomer armodafinil product and related pharmaceutical compositions. Cephalon obtained a judgment that the asserted claims were not invalid for obviousness, and the Federal Circuit affirmed. The case preserved Cephalon’s patent position against Mylan through the remaining term of the patent, although later generic entry occurred after patent expiration.

What drug and patent were involved in Cephalon v. Mylan?

The litigation concerned armodafinil, the R-enantiomer of modafinil and the active ingredient in Nuvigil.

Item	Detail
Brand drug	Nuvigil
Active ingredient	Armodafinil
Sponsor at filing	Cephalon Inc.
Generic applicant	Mylan Pharmaceuticals Inc.
FDA pathway	ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case number	1:12-cv-00247
Principal patent	U.S. Patent No. 7,132,570
Patent subject matter	Armodafinil and pharmaceutical compositions containing the enantiomer
Federal Circuit appeal	Cephalon, Inc. v. Mylan Pharmaceuticals Inc., 817 F.3d 1316 (Fed. Cir. 2016)

Nuvigil was approved by the FDA in 2007 for improving wakefulness in adults with excessive sleepiness associated with obstructive sleep apnea, shift-work sleep disorder, and narcolepsy. Mylan’s ANDA triggered a Paragraph IV certification asserting that the patent was invalid, unenforceable, or would not be infringed.

What patents protected Nuvigil and armodafinil?

The central patent was U.S. Patent No. 7,132,570, commonly referred to as the ’570 patent. The patent protected armodafinil as a distinct enantiomer of modafinil and covered pharmaceutical compositions containing the compound.

The patent dispute focused on whether a skilled person would have been motivated to isolate the R-enantiomer from racemic modafinil and whether the resulting compound had unexpected properties sufficient to overcome an obviousness challenge.

The Orange Book-listed patent estate for Nuvigil included the ’570 patent during the relevant litigation period. Other Cephalon patents and regulatory exclusivities were commercially relevant to Nuvigil, but the Delaware action against Mylan centered on the ’570 patent.

What did the ’570 patent claim?

The asserted claims covered armodafinil and compositions containing predominantly the R-enantiomer. Cephalon’s infringement theory was based on Mylan’s proposed generic product, as described in its ANDA.

Mylan did not rely primarily on a non-infringement position. The decisive issue was validity, particularly obviousness under 35 U.S.C. § 103.

Why did Mylan challenge Cephalon’s patent?

Mylan argued that armodafinil was obvious in view of prior art concerning modafinil, including:

• The known racemic modafinil compound.
• The existence of enantiomers and the possibility of separating them.
• Prior research suggesting that the two enantiomers could have different pharmacological properties.
• Conventional techniques for resolving chiral compounds.
• Evidence that the R-enantiomer had been identified or could be obtained through ordinary pharmaceutical research.

Mylan’s position was that a skilled artisan would have pursued the individual enantiomers and would have had a reasonable expectation of success.

Cephalon argued that the prior art did not provide a sufficient reason to isolate armodafinil, did not predict its clinically relevant properties, and did not establish that the R-enantiomer would provide a useful therapeutic advantage over racemic modafinil.

What was the key legal issue in the case?

The principal legal issue was whether the asserted claims of the ’570 patent were obvious.

For an obviousness analysis, the court considered:

1. The scope and content of the prior art.
2. Differences between the prior art and the asserted claims.
3. The level of ordinary skill in the art.
4. Objective indicia of non-obviousness, including unexpected results and commercial success.

The case was important because it addressed the patentability of a single enantiomer derived from a known racemic drug. The existence of a racemate does not automatically make a later enantiomer patent obvious. The court examined whether the prior art supplied a reason to make the specific selection and whether the result was reasonably predictable.

What did the Delaware district court decide?

The district court ruled in Cephalon’s favor after evaluating Mylan’s invalidity arguments. The court concluded that Mylan had not shown the asserted claims to be invalid for obviousness.

The court’s analysis credited several points favorable to Cephalon:

• The prior art did not establish a clear motivation to isolate armodafinil for the claimed therapeutic purpose.
• The pharmacological differences between enantiomers were not sufficiently predictable.
• Armodafinil demonstrated properties that Cephalon characterized as unexpectedly useful.
• The evidence did not establish a strong reasonable expectation of success.
• Objective evidence supported the patent’s validity.

Mylan challenged the judgment on appeal, arguing that the district court applied the obviousness framework too narrowly and gave excessive weight to unexpected results.

What did the Federal Circuit decide?

In 2016, the Federal Circuit affirmed the district court’s judgment. The appellate court held that the district court did not clearly err in finding the asserted claims non-obvious. Cephalon, Inc. v. Mylan Pharmaceuticals Inc., 817 F.3d 1316 (Fed. Cir. 2016).

The Federal Circuit’s reasoning preserved several principles relevant to pharmaceutical patent litigation:

A known racemate does not automatically invalidate an enantiomer patent

The court rejected the proposition that a known racemic compound necessarily creates a prima facie case that each individual enantiomer is obvious. The analysis depends on the prior art’s teaching, the motivation to separate the enantiomers, and the predictability of the resulting properties.

Routine separation does not resolve the entire obviousness inquiry

Even if the chemical techniques for separating enantiomers were known, the court distinguished the ability to perform a separation from the reason to select a particular enantiomer and develop it as a drug.

Unexpected properties can support validity

Cephalon relied on evidence that armodafinil had clinically useful characteristics that were not predictable from the prior art. The Federal Circuit accepted the district court’s evaluation of that evidence.

Deference to fact findings mattered

The appellate court reviewed the district court’s factual findings for clear error. That standard limited Mylan’s ability to overturn the trial result after a developed evidentiary record.

Was there a Paragraph IV certification?

Yes. Mylan’s ANDA filing generated a Paragraph IV dispute because Mylan asserted that the relevant Cephalon patent was invalid or would not be infringed.

Cephalon filed suit within the statutory period after receiving Mylan’s Paragraph IV notice. The filing triggered the Hatch-Waxman 30-month stay of FDA approval, subject to litigation developments and statutory exceptions.

Hatch-Waxman issue	Case impact
ANDA filing	Mylan sought approval for generic armodafinil
Paragraph IV certification	Mylan challenged the ’570 patent
Patent litigation	Cephalon filed in Delaware
30-month stay	Delayed final FDA approval during the statutory period
Trial issue	Validity, principally obviousness
Appeal	Federal Circuit affirmed Cephalon’s judgment

When did Nuvigil lose patent exclusivity?

The ’570 patent had an expiration date in 2024, including patent-term adjustment reflected in the relevant patent and Orange Book records. The practical exclusivity period for Nuvigil was also affected by FDA regulatory exclusivity, litigation timing, and any agreements involving other ANDA applicants.

Nuvigil’s commercial protection was therefore not determined by the patent expiration date alone. The relevant timeline included:

Date or period	Event
2007	FDA approval of Nuvigil
February 2012	Cephalon filed the Delaware action against Mylan
2015	District court proceedings and validity determination
2016	Federal Circuit affirmed the judgment
2024	Expiration period for the principal ’570 patent, subject to applicable Orange Book and patent-term records

The exact first generic-launch date depended on FDA approval of individual ANDAs and any applicable settlement or exclusivity rights.

What was the litigation outcome for Mylan?

Mylan did not invalidate the ’570 patent in the Cephalon action. The Federal Circuit’s affirmance meant that Mylan’s Paragraph IV invalidity challenge failed on the appellate record.

The judgment did not create a permanent bar against future generic armodafinil products. It preserved the patent’s enforceability against the accused Mylan ANDA through the patent term. Once the patent expired, the legal basis for blocking a conforming generic product ended, subject to other valid and enforceable patents or regulatory barriers.

Did the case involve formulation patents or method-of-use patents?

The litigation was principally a compound and composition patent dispute involving armodafinil. It was not primarily a dispute over a narrow dosage regimen or a device-based delivery system.

Nuvigil’s broader commercial patent position could include:

• Active-ingredient or enantiomer claims.
• Pharmaceutical-composition claims.
• Formulation claims.
• Method-of-use claims directed to wakefulness disorders.
• Manufacturing or purification claims.

The Mylan case should therefore be distinguished from litigation focused exclusively on a labeled indication or a specific dosage schedule. A generic applicant can sometimes avoid a method-of-use patent through a section viii carve-out, but that strategy does not avoid a valid patent covering the active ingredient or the generic composition itself.

How strong was Cephalon’s patent estate?

The ’570 patent proved strong against Mylan’s obviousness challenge because it survived both district court review and Federal Circuit appeal. Its strength came from the factual record surrounding enantiomer selection, unpredictability, and unexpected properties.

Strength factor	Assessment
Claim scope	Broad enough to cover the active enantiomer and drug composition
Validity record	District court upheld the claims
Appellate record	Federal Circuit affirmed
Obviousness exposure	Material, because modafinil was known
Infringement exposure	High for an ANDA product containing armodafinil
Lifecycle limitation	Protection was tied to the patent term
Regulatory durability	Depended on patent listing and FDA approval timing

The patent was stronger than a narrow method-of-use patent against an ANDA applicant because a product containing the patented active enantiomer would directly implicate the composition claims.

What generic entry risks existed for Nuvigil?

Before patent expiration, the primary entry risk was an adverse validity decision or a settlement allowing an earlier launch. The Federal Circuit affirmance reduced the immediate risk from Mylan’s challenge but did not eliminate all generic-entry exposure.

The main entry scenarios were:

1. Judgment-based entry after patent expiration.
   Mylan could enter after expiration of the blocking patent if FDA approval was available.

2. Settlement-based early entry.
   Cephalon could authorize an earlier launch through a settlement, subject to antitrust and Hatch-Waxman considerations.

3. Independent invalidity or non-infringement decisions.
   Other ANDA applicants could pursue different factual records or claim constructions.

4. At-risk launch.
   A generic applicant could launch before final resolution, accepting potential damages and injunction exposure.

5. Non-infringing formulation strategy.
   This was less significant where the patent claims covered the active armodafinil compound or composition.

Were biosimilars relevant to this case?

No. Nuvigil is a small-molecule drug, not a biologic. The applicable competition pathway was the ANDA pathway for generic drugs, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive products were generic armodafinil tablets. Biosimilar interchangeability, reference-product exclusivity, and biologic patent dance procedures did not apply.

What was the commercial significance of the litigation?

The case protected Cephalon’s ability to maintain Nuvigil sales against Mylan during the remaining patent term. Nuvigil was a successor product to Provigil, with armodafinil positioned as the single-enantiomer follow-on product to modafinil.

Commercial exposure depended on:

• Nuvigil prescription volume.
• Net price after rebates.
• The timing of generic armodafinil approval.
• The number of approved ANDA applicants.
• Substitution rates at pharmacies.
• Payer formulary treatment.
• The availability of alternative wakefulness drugs, including modafinil and stimulants.

The litigation outcome reduced the risk of immediate Mylan competition, but it did not prevent eventual erosion after patent expiry. Once multiple generic suppliers entered, price compression and rapid share migration were likely for a mature oral small-molecule product.

What licensing deals and settlements affected Nuvigil?

The reported public record for this specific docket is centered on the Cephalon-Mylan litigation and Federal Circuit appeal. The case outcome should not be treated as evidence that all Nuvigil-related ANDA disputes ended identically. Cephalon and other Nuvigil stakeholders faced separate disputes involving other generic applicants, and settlements in related Hatch-Waxman matters could have different launch dates and terms.

No settlement should be attributed to Mylan in this docket unless supported by a filed agreement or court record. The reported appellate outcome was an affirmance of Cephalon’s judgment, not a public settlement disposition.

What is the FDA and Orange Book status of Nuvigil?

Nuvigil was FDA-approved as armodafinil tablets. The Orange Book listed the relevant patent protection for the reference product during the period in which the Mylan ANDA was litigated.

For commercial diligence, the key distinction is:

• FDA approval establishes the regulatory basis for marketing.
• Orange Book listing identifies patents associated with the reference product.
• A Paragraph IV certification creates the patent dispute.
• A court judgment determines whether the challenged patent survives that dispute.
• Patent expiration removes the principal patent-based barrier, but FDA approval remains necessary.

Key Takeaways

• Cephalon sued Mylan in Delaware after Mylan filed an ANDA with a Paragraph IV certification for generic armodafinil.
• The principal patent was U.S. Patent No. 7,132,570.
• The decisive issue was whether armodafinil, the R-enantiomer of modafinil, was obvious.
• The district court found the asserted claims non-obvious.
• The Federal Circuit affirmed in 2016.
• The decision protected Nuvigil against Mylan’s challenge through the remaining patent term.
• The case involved a small-molecule generic, not a biosimilar.
• Generic entry remained possible after patent expiration or through a settlement-based early-launch arrangement.
• The ’570 patent was stronger than a narrow method-of-use patent because it covered the active enantiomer and pharmaceutical compositions.
• Nuvigil’s eventual revenue exposure was driven by patent expiry, FDA approvals, generic count, substitution, and payer behavior.

FAQs

What was the patent number in Cephalon v. Mylan?

The principal patent was U.S. Patent No. 7,132,570, covering armodafinil and related pharmaceutical compositions.

Did Mylan win the Nuvigil patent lawsuit?

No. The district court ruled for Cephalon on validity, and the Federal Circuit affirmed that judgment in 2016.

Was armodafinil considered obvious because modafinil was already known?

Not automatically. The courts held that the known racemate did not establish that selecting and developing the R-enantiomer was obvious on the evidence presented.

Could Mylan launch generic armodafinil before the ’570 patent expired?

Only through a successful invalidity or non-infringement outcome, an authorized settlement, or another legally permissible launch strategy. The judgment in this case did not authorize an early launch.

Is Nuvigil protected by biologic exclusivity?

No. Nuvigil is a small-molecule drug. Its competition is governed by Hatch-Waxman and ANDA rules, not biosimilar exclusivity rules.

References

1. Cephalon, Inc. v. Mylan Pharmaceuticals Inc., 817 F.3d 1316 (Fed. Cir. 2016).

2. U.S. District Court for the District of Delaware. (2012). Cephalon Inc. v. Mylan Pharmaceuticals Inc., No. 1:12-cv-00247.

3. U.S. Food and Drug Administration. (2007). Nuvigil (armodafinil) prescribing information. https://www.accessdata.fda.gov

4. U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,132,570: Armodafinil-related pharmaceutical compositions and uses. https://patents.google.com/patent/US7132570

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book